Kornimate/medical-research-clean huggingface dataset:
prevalence of food allergies to proteins from different legumes

Conditions: Food Allergy

Summary: the objective of the study is to assess the prevalence of a sensitization to proteins from legumes by skin prick test using commercial extracts (peanut, soy, and pea) and raw material (lupin) in atopic and healthy subjects.


Eligibility criteria:
1. inclusion criteria: * male and female subjects * age 18 up to 75 years * for group "atopic": either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of erlangen (\>10 points). 2. exclusion criteria: * intake of antihistamines, tricyclic antidepressants, systemic corticosteroids * acute allergic symptoms * skin infections at the test side * pregnancy, lactation * acute inflammatory diseases

Keywords: lupin peanut soy pea legumes cross-reactivity sensitization atopy
study to evaluate the safety and efficacy of atyr1923 (efzofitimod) in participants with severe pneumonia related to covid-19

Conditions: SARS-CoV-2 (COVID-19) Severe Pneumonia

Summary: to evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with sars-cov-2 (covid-19) severe pneumonia not requiring mechanical ventilation.


Eligibility criteria:
inclusion criteria: * confirmation of sars-cov-2 infection by polymerase chain reaction (pcr). * severe pneumonia related to sars-cov-2 infection, defined as fever or suspected respiratory infection with radiographic abnormalities suggestive of viral pneumonia, plus at least 1 of the following: * respiratory rate \>30 breaths/minute; * severe respiratory distress, as determined by the investigator; * oxygen saturation (spo2) ≤93% on room air. exclusion criteria: * participant is intubated/mechanically ventilated. * in the opinion of the investigator, participant's progression to death is imminent. * treatment with immunosuppressant/immunotherapy drugs, including but not limited to interleukin (il)-6 inhibitors, tumor necrosis factor-alpha (tnf-α) inhibitors, anti-il-1 agents and janus kinase inhibitors within 5 half-lives or 30 days prior to day 1. * use of chronic (\>30 days) oral corticosteroids for a non-covid-19-related condition in a dose higher than prednisone 10 mg or equivalent per day. * weight \>165 kg or \<40 kg.

Keywords: sars-cov-2 cov-2 atyr1923 (efzofitimod) acute respiratory distress syndrome ards sars-cov-2 infection covid-19 severe pneumonia
the investigator administers intracoronary adrenaline via the catheter in stemi patients during primary pci, after flow restoration and before stenting, and studies its effect in prevention of no reflow

Conditions: ST Segment Elevation Myocardial Infarction (STEMI); No Reflow Phenomenon

Summary: the aim of this work is to study the role of intracoronary adrenaline administration as a preventive tool for no reflow in patients undergoing primary pci. the main question it aims to answer is: do prohylcatic intrcoronary adrenaline reduce the incidence of no reflow without increaing risk of arrhythmia in primary pci? the procedure will be performed by expert operators. all patients will receive the guidelines-directed recommendations of intervention of stemi patients. study group wil receive intracoronary 10 mcg adrenaline via the guiding catheter after restoration of epicardial coronary flow of the culprit vessel and achievement of timi i flow either after wiring and/or passage of a deflated balloon and/or ptca with a small balloon, and/or use of thrombus aspiration and before stenting. all steps in the cath-lab will be described in detail: the primary end points will be improvement in coronary flow, as assessed by timi (thrombolysis in myocardial infarction) flow, and myocardial blush. secondary end points will be in-hospital mortality and major adverse cardiac events.


Eligibility criteria:
inclusion criteria: 1. patients who are 18 years or older 2. patients presenting with acute coronary syndrome with ecg criteria diagnostic of stemi (according to the universal definition of myocardial infarction) within 12 hours from the onset of symptoms and treated by successful primary pci. exclusion criteria: 1. age \< 18 years 2. pregnant females. 3. patients refused to give consent. 4. patients who had normal coronary angiography. 5. patients who had cto lesions. 6. patients who have scad. 7. patients who developed dissection or mechanical complication during the procedure. 8. patients presenting with cardiogenic shock. 9. cardiomyopathies 10. contraindications to epinephrine as htn with sbp \>180 mmhg or dbp\>110 mmhg, clinically significant arrhythmia (atrial fibrillation with rapid ventricular rate, ventricular tachycardia, or ventricular fibrillation) prior to pci, known allergy to epinephrine.

Keywords: stemi no-reflow adrenaline prophylaxis
efficacy and safety of carbidopa/levodopa/entacapone in patients with parkinson's disease requiring initiation of levodopa therapy

Conditions: Parkinson's Disease

Summary: the celc200a2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic parkinson's disease * diagnosis of parkinson's disease for no more than 5 years exclusion criteria: * history, signs, or symptoms of atypical or secondary parkinsonism * presence at baseline of drug-related wearing-off symptoms, dyskinesia or other motor complications * levodopa exposure of more than 30 days or anytime within 8 weeks prior to visit 1 other inclusion/exclusion criteria applied to this study.

Keywords: parkinson's disease, levodopa therapy, dyskinesia
nutritional status of critically ill diabetic patients

Conditions: Nutrition; Critical Illness; Diabetes Mellitus, Type 2

Summary: 1. to investigate the nutritional status of patients with type 2 diabetes mellitus in the intensive care unit. 2. to detect the impact of nutritional status on outcome (mortality, length of hospital stay,duration of mechanical ventilation, and need for renal replacement therapy)

nutrition support in the intensive care unit is very important since it has a significant impact on recovery from illness and overall outcome. patients in the intensive care unit have a higher risk of malnutrition than patients undergoing general admission to hospitals . in critically ill patients, malnutrition may result in impaired immunological function, impaired ventilatory drive, and weakened respiratory muscles, leading to prolonged ventilatory dependence and increased infectious morbidity and mortality. an appropriate nutritional support is indispensable to critically ill patients, who are almost at the hyper-metabolic state of their clinical condition such as trauma, sepsis, and major surgery. these critical conditions result in a disproportional release of cytokine and stress hormones that alter energy and protein metabolism and eventually lead to malnourishment. a recent systematic review revealed the strikingly high prevalence of malnutrition in intensive care unit patients (ranged from 38% to 78%), which is associated with the patients' increased morbidity, mortality, and hospital-related cost.the increased dependency on mechanical ventilation, length of hospital stay, intensive care unit readmission, persistence of infection, and risk of hospital mortality associated with undernutrition, make it an important dilemma in the care of intensive care unit patients. diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. insulin is a hormone that regulates blood glucose.( and associated with serious complications, demand for multimodal treatment, and significant economic burden with the development of complications and hospital lengths of stay, life expectancy is worsened with diabetes, and nutritional status is generally correlated with these total outcomes. in this research,investigators will evaluate the nutritional state in critically ill diabetic patients with type 2 diabetes mellitus, and detect the impact of poor nutritional status on out comes regarding mortality, length of hospital stay , length of mechanical ventilation, and need for renal replacement therapy.

Eligibility criteria:
inclusion criteria: age above 18 years. diabetic type ll. admitted for more than 48 hours. exclusion criteria: type 1 diabetes mellitus. age under 18 years readmission in intensive care unit. adimssion for less than 48 hours
genotype-phenotype correlation in junctional epidermolysis bullosa

Conditions: Junctional Epidermolysis Bullosa; Laryngo Onycho Cutaneous Syndrome

Summary: this study will collect genetic and clinical information of junctional epidermolysis bullosa (jeb) patients. computer analysis will be performed on genetic mutations found in these patients and this will be correlated with their clinical characteristics.

junctional epidermolysis bullosa (jeb) is a rare genetic skin disease where genetic defects in skin proteins result in extensive blistering in response to mild mechanical stress. patients are often affected at birth or from early childhood, and suffer from varying degrees of severity depending on the specific mutations that they have and the proteins that are affected. this ranges from severe widespread blistering and death within the first few years of life, to minimal localised blistering and survival to adulthood. diagnosis is confirmed by genetic testing, and this is often used to predict the likely clinical course. however, it is not always straightforward to make accurate predictions from genetic information, as our understanding of these proteins and mutations at the molecular level is currently incomplete. the main aim of this project is to systematically collect genetic and clinical data of junctional epidermolysis bullosa (jeb) patients and to explore whether there are any relationships between participants' genetic defects and the severity of disease. this will help in establishing links between genetic defects and clinical characteristics, which is essential for accurate prognostication, genetic counselling and prenatal diagnosis. this study will also aim to develop pipelines for analysis of how mutations may affect corresponding protein structure and function using computer prediction tools. this will improve our understanding of how these proteins function, and could partly explain the variation in disease severity of patients with this condition. it could also lead to identification of important regions of the protein, which could be investigated further in subsequent studies.

Eligibility criteria:
inclusion criteria: adults and children with a diagnosis of jeb or loc syndrome, which has been confirmed with genetic testing. a mutation is present in one of the following genes: lama3, lamb3, lamc2 or col17a1. current jeb patients, or jeb patients within the last 5 years who have used the eb service at solihull hospital or birmingham women's and children's hospital. this includes patients who are living and also those who passed away in the last 5 years (eg from severe jeb). exclusion criteria: adult patients who are unable to give informed consent. child patients who do not assent and/ or have no one appropriate who can consent on their behalf. persons who might not adequately understand verbal explanations or written information given in english.

Keywords: open access database junctional epidermolysis bullosa genotype phenotype correlation
safety and efficacy of genakumab for injection in patients with gout flare

Conditions: Acute Gout; Gout Flare

Summary: to evaluate the safety and efficacy of genakumab for injection in patients with gout flare as a first line therapy

phase 2， randomized, open lable, multi-center, active controlled study. patients are randomized to genakumab 200mg single injection group or etoricorxib 120mg qd po.(until remission or intorlerance, no longer than 8 days) group.

Eligibility criteria:
1. male or female, 18 years ≤ age ≤ 75 years; 2. bmi ≤ 40kg/m2 3. meeting acr 2015 preliminary criteria for the classification of acute arthritis of primary gout; 4. start of acute gout flare within 3 days prior to enrolled; 5. history of ≥2 gout flare within 12 months prior to study start; 6. baseline pain intensity ≥ 50mm on the 0-100mm visual analog scale(vas)

Keywords: acute gout gout flare
efficacy of intralesional injection of platelet rich plasma in the treatment of patients with erosive oral lichen planus

Conditions: Erosive Oral Lichen Planus

Summary: after signing the informed consent, the participant will be allocated to either intervention or control group, then each participant in the intervention group will receive intralesional injections of platelet rich plasma extracted from their own blood in each visit as following: 1. 12 ml of blood will be assembled from the veins of antecubital fossa 2. prp preparation will be done according to mostafa et al., 2013 3. 0.5 ml of prp will be injected per 1 cm2 of ulcerated mucosa the second group will receive triamcinolone acetonide 40 mg injected 1 ml per 1 cm2 of ulcerated mucosa both groups will receive a total of 4 injection, the injections will be carried out once a week. pain, lesions size and remission time are the outcomes will be assessed using a numerical rating scale (seymour, 1982), clinical score according to thongprasom et al., 1992 and binary scale for remission time according to conrotto et al., 2006, respectively. assessment of the outcomes will be carried before the trial (baseline records) and before receiving the treatment in each visit by the primary investigator (h.a.) and the blinded assessor (dr. a.w.) separately. each participant will have a total of 11 visits during the trial, 5 visits will be once every week during the trial and every 2 weeks for 3 months treatment free.


Eligibility criteria:
inclusion criteria: * patients presenting with a clinical picture that assumes the diagnosis of erosive oral lichen planus (bilateral, more or less symmetrical erosive lesions with lacelike network of slightly raised gray white lesions (reticular pattern), and a histological findings that confirms the diagnosis (liquefaction degeneration of the basal cell layer with irregular-saw teeth like rete pegs. exclusion criteria: * systemic disorders such as hematological diseases, severe cardiovascular diseases, treatment with any drugs that could cause lichenoid reaction. * pregnancy or active breastfeeding * patients who had lesion/lesions with dysplasia * patients who received topical treatment for oral lichen planus in the last 2 weeks (lee et al., 2013) or systemic treatment for olp in the past 3 months. * platelet count \< 150,000/mm3; hgb \< 11 g/dl. * immunosuppressed patients * patients receiving therapy with anticoagulants and use of non-steroidal anti-inflammatory drugs in the 5 days before taking the blood sample.

Keywords: oral lichen planus prp
a phase 3 trial of ly900003 plus gemcitabine and cisplatin versus gemcitabine and cisplatin in patients with advanced, previously untreated non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purposes of this study are to determine: 1. if treatment with ly900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2. the safety of ly900003 plus gemcitabine and cisplatin and any side effects that might be associated with the combination of these three drugs. 3. whether ly900003 plus gemcitabine and cisplatin can make your tumor smaller or disappear, and for how long, compared with gemcitabine and cisplatin alone. it is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate ly900003 plus gemcitabine and cisplatin for other possible uses or for other medical or scientific purposes other than those currently proposed. ly900003 may not add any benefit to gemcitabine plus cisplatin.


Eligibility criteria:
inclusion criteria: 1. stage iiib or iv non-small lung cancer 2. able to visit the doctor's office 3. at least 18 years of age 4. adequate kidney, adrenal, and liver function exclusion criteria: 1. prior chemotherapy or biologic therapy for nsclc 2. central nervous system tumors 3. pregnant or breastfeeding

Keywords: non-small cell lung cancer stage iiib or iv non-small cell lung cancer (nsclc)
manual therapy versus exercise on knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: earlier research has shown that exercising while receiving manual therapy improves function and reduces pain in people with knee osteoarthritis. however, very little is known about the mechanisms by which manual therapy and exercise reduce pain and improve function. this study will ask subjects with knee osteoarthritis to receive one of the following interventions: (1) no treatment, (2) exercise only, or (3) manual therapy only. measures will be taken of the patient's knee range of motion, knee swelling and pain before and after receiving the intervention. these measures will be analyzed to determine what effect exercise and manual therapy applied to the knee have on improving knee range of motion and reducing knee pain and swelling. swelling will be measured using an ultrasound device which is used to take pictures inside the knee. this type of ultrasound measurement is painless and harmless.


Eligibility criteria:
inclusion criteria: * diagnosis of knee osteoarthritis. exclusion criteria: * inability to ambulate at least 100 feet, ride a stationary bicycle for at least 10 minutes, or lie in the prone position for at least 10 minutes, * intra-articular knee injection within one month of study inception, * a history of exercise induced or uncontrolled angina within three months of the study entry, * severe dyspnea at rest, * previous bilateral total knee arthroplasty, * pregnancy, or * the absence of knee pain at the time of recruitment for the study.

Keywords: knee osteoarthritis manual therapy therapeutic exercise ultrasound effusion
comparison of theraband, co-contraction and isometric exercises in frozen shoulder

Conditions: Frozen Shoulder

Summary: this project was a randomized control trial conducted to check the effects of in patients with chronic frozen shoulder theraband, isometric and co-contraction exercises so that we can have best treatment option for patients with chronic frozen shoulder. upper cross syndrome, duration was of 6months,convenient sampling was done, subject following eligibility criteria from dhq hospital sheikhupura, were randomly allocated in three groups via lottery method, baseline assessment was done, group a participants were given baseline treatment along with theraband exercises , group b participants were given baseline treatment along with co-contraction exercises and group c were given baseline treatment along with isometric exercises on 3rd and 6th week, post intervention assessment was done via, numeric pain rating scale(nprs),shoulder pain and disability index (spadi) and goniometric measurements of shoulder ranges ,3 sessions per week were given, data was analyzed by using spss version 26.

frozen shoulder is among the most commonly reported problems to physicians, orthopedics and physical therapists. even before reporting to clinics there is long history of using over the counter pain killers. pain avoidance behaviors let the joint stiff so much that a clinician help is sought. most times the cause of frozen shoulder is not known, therefore is termed as 'idiopathic frozen shoulder'.there is huge literature regarding the management of frozen shoulder and yet after the decades of research there are gaps in treatment options. in modern age of health care, it is common goal of every health care to make patient self-sufficient as early as possible. the self-care models have tremendous advantages. the current study has compared the use of theraband, co-contraction and isometric exercises. the current study was novel in a way that there is limited literature about treating shoulder hypomobility with physical strengthening exercises. all three methods were employed to see if they improve ranges along with accompanying pain and disability.

Eligibility criteria:
inclusion criteria: * idiopathic with 6 month chronicity. * patients with arom/prom less than or equal to 90 degrees. * affected shoulder has not more than 90 degrees of abduction \& 50% decreased external rotation as compared to normal side/normal rom values. exclusion criteria: * traumatic \& diabetic. * patient with any cervical or thoracic problem. * patients with any intra-articular injection in glenohumeral joint. * patients with rotator cuff complete tear. * patients with any other serious pathology/red flags

Keywords: theraband co-contraction isometric frozen shoulder
symptom management and transitioning to engagement with post-treatment care for adolescent and young adult cancer survivors

Conditions: Cancer; Breast Cancer; Colorectal Cancer; Sarcoma; Lymphoma; Testicular Cancer

Summary: the purpose of this study is to determine the effectiveness of a digital health program called aya steps, which is designed to help adolescent and young adult (aya) cancer survivors manage symptoms and engage in recommended follow-up care.

the investigators have developed an accessible digital health intervention, aya steps (symptom management and transitioning to engagement with post-treatment care for aya survivors), designed to enhance adolescent and young adult (aya) cancer survivors' abilities to manage their high symptom burden and engage in follow-up health care. informed by the obesity-related behavioral intervention trials (orbit) model of intervention development, aya steps has been systematically and rigorously developed and refined through the pi's prior work (k08ca245107). aya steps is organized into six remotely delivered sessions providing cognitive-behavioral and patient activation theory-based skills expected to lead to lower symptom burden and increased health care engagement by improving ayas' self-efficacy for symptom management and activation. the investigators propose a randomized controlled trial to examine the efficacy of aya steps compared to aya educational information for improving symptom burden and health care engagement for aya survivors (n=260) who received cancer care in diverse health care settings (i.e., rural, urban, medically underserved areas) across north carolina. self-efficacy and patient activation will be examined as mediators of intervention effects. the planned study has the potential to produce clinically impactful health benefits for an underserved and understudied group of cancer survivors who have significant symptom burden, experience barriers to care engagement, and have limited access to aya-specific behavioral interventions.

Eligibility criteria:
inclusion criteria: * diagnosed with one of the following cancers: 1) stage i-iii breast cancer; 2) stage i-iii colorectal cancer; 3) stage i-iii sarcoma; 4) stage i-iii hodgkin or non-hodgkin lymphoma; or 5) stage i-ii testicular cancer * treated with curative intent and off therapy (with the exception of endocrine/hormonal therapy) for the last three months * 1 to 5 years post-diagnosis * able to speak and read english * able to give informed consent exclusion criteria: * moderate or severe cognitive impairment * severe untreated mental illness (e.g., schizophrenia, substance use disorder) that would interfere with providing meaningful consent/study participation

Keywords: cancer young adult behavioral symptom management